J Cancer 2016; 7(5):569-575. doi:10.7150/jca.13637

Research Paper

Comparison of the Control of Nausea and Vomiting among Several Moderately Emetic-Risk Chemotherapy Regimens

Hirotoshi Iihara1✉, Masashi Ishihara1, Hironori Fujii 1, Chiaki Yoshimi 1, Maya Yamada 1, Akio Suzuki1, Kazuya Yamaguchi2, Manabu Futamura2, Kazuhiro Yoshida 2, Yoshinori Itoh1

1. Department of Pharmacy, Gifu University Hospital, Gifu, Japan;
2. Department of Surgical Oncology, Gifu University Graduate School of Medicine, Gifu, Japan.

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) License. See http://ivyspring.com/terms for full terms and conditions.
Iihara H, Ishihara M, Fujii H, Yoshimi C, Yamada M, Suzuki A, Yamaguchi K, Futamura M, Yoshida K, Itoh Y. Comparison of the Control of Nausea and Vomiting among Several Moderately Emetic-Risk Chemotherapy Regimens. J Cancer 2016; 7(5):569-575. doi:10.7150/jca.13637. Available from http://www.jcancer.org/v07p0569.htm

File import instruction


Background: Different antiemetic medications with or without aprepitant are recommended for moderately emetic-risk chemotherapy (MEC) depending on the emetic potential of chemotherapy agents, although the criterion for the use of aprepitant is still unclear. The present study was designed to compare the control of chemotherapy-induced nausea and vomiting (CINV) among several MEC regimens used in the outpatient chemotherapy setting. Materials and Methods: A single center prospective observational study was carried out in 326 patients who received 2,061 chemotherapy cycles from January 2013 to December 2014. Antiemetic medication consisting of two-drug combination of granisetron (day 1) and dexamethasone (days 1-3) was carried out in 87.6% of patients receiving the first chemotherapy cycle. The checklist for CINV was provided to all patients, and the control of CINV was evaluated on the next visit based on the checklist. Complete inhibition of nausea and vomiting during acute and delayed periods were compared among MEC regimens. Results: Two hundred and one patients received the first cycle of chemotherapy, in which the rates of complete inhibition of nausea and vomiting were 87.6% and 95.5%, respectively, during acute period, and 68.2% and 92.0%, respectively, during delayed period. There were no significant differences in the control of CINV among oxaliplatin, carboplatin and irinotecan, except for the cyclophosphamide-base regimen.

Conclusions: Two-drug antiemetic medication of 5-HT3 receptor antagonist and dexamethasone was sufficiently effective for prevention of CINV in most MEC regimens.

Keywords: moderately emetic-risk chemotherapy - nausea - vomiting - outpatient cancer chemotherapy.